Phase 1 Prostate Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with castration-resistant prostate cancer (a form of prostate cancer that has continued to grow despite hormone-reducing treatment) who have already been through three lines of treatment
• People who have given written consent to participate and are able to follow the study schedule, including attending appointments and completing treatments
• People with a life expectancy of more than 3 months
• People who have at least one area of cancer that can be clearly measured by CT or MRI scan at the start of the study and monitored over time
• People who have a physical functioning level rated at 2 or below on a standard medical scale, meaning they are able to care for themselves but may not be able to do active work (confirm with trial site)
• People aged 18 or older, with no upper age limit
• Male participants who are sexually active with a partner who could become pregnant must agree to use two highly effective forms of contraception, starting from when consent is signed and continuing for 3 months after the last dose of study treatment
• People whose blood, kidney, and liver test results fall within the required ranges when tested within 14 days before starting treatment — including acceptable levels of red blood cells, white blood cells, platelets, liver enzymes, kidney function markers, and blood clotting measures (confirm specific values with the trial site)

Who may not be able to join:

• People who have had another cancer in the last 5 years, except for certain treated non-melanoma skin cancers
• People who have taken part in another clinical trial involving an experimental cancer treatment within the past 30 days
• People still experiencing significant side effects (rated Grade 2 or higher) from a previous cancer treatment, with the exception of hair loss or mild nerve-related side effects
• People showing signs of a serious active infection
• People with a history of HIV infection
• People with a weakened immune system
• People with active or long-term hepatitis B or C infection
• People with a history of autoimmune disease (where the body's immune system attacks its own tissues)
• People with a significant history of, or currently experiencing, serious brain or nervous system conditions — such as seizures, stroke, severe brain injury, dementia, Parkinson's disease, psychosis, or movement disorders — or epilepsy that requires medication
• People currently on blood-thinning (anticoagulation) medication as a treatment
• People who have had major surgery within 4 weeks before starting the study, or who have not yet fully recovered from major surgery
• People who have received chemotherapy or radiotherapy within 2 weeks before starting the study (or longer, depending on the treatment used)
• People with severe heart failure (rated at the two most serious levels on a standard heart failure scale)
• People with a severe breathing disorder affecting airflow in or out of the lungs
• People with a known history of a hole or tear in the digestive tract (gastrointestinal perforation)
• People with a pre-existing condition known as HAHA (confirm with trial site)
• People with a known allergy or intolerance to CC-1, tocilizumab, other similar antibody-based medicines, or any of their ingredients

Important: Always verify eligibility with the trial site directly before applying.